Skip to content

Meropenem population pharmacokinetics in critically ill patients

Meropenem population pharmacokinetics in critically ill patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900026224
Enrollment
Unknown
Registered
2019-09-27
Start date
2019-09-30
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various infectious diseases in the ICU

Interventions

Meropenem anti-infective group:Meropenem anti-infective

Sponsors

Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Receive treatment at the ICU ward of the Third Xiangya Hospital of Central South University. 2. Age is greater than 18 years old. There are no restrictions on gender, body weight, primary disease or underlying disease, comorbidities, liver and kidney function, and other organ functions (including antibiotics). 3. Patients need anti-infective treatment with meropenem for clinical treatment, and the course of treatment is expected to be at least 3 days.

Exclusion criteria

Exclusion criteria: The clinician believes that the patient is not suitable for this clinical study.

Design outcomes

Primary

MeasureTime frame
Meropenem plasma concentration;

Countries

China

Contacts

Public ContactQi Pei

The Third Xiangya Hospital, Central South University

peiqi1028@126.com+86 13170419804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026